TRIPARNA SEN

@triparnasen

Lung cancer researcher studying . Advocate of equal opportunity for . Always curious. Bookworm.Traveler.Tweets mine

New York, USA
Vrijeme pridruživanja: ožujak 2011.

Tweetovi

Blokirali ste korisnika/cu @triparnasen

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @triparnasen

  1. proslijedio/la je Tweet

    Here’s the bottom line: $297 million budget boost for in FY 2020 = we are extending paylines and anticipate funding more than 125 additional competing awards this fiscal year than we did in FY 2019. More detail in today’s “Bottom Line” blog post:

    Prikaži ovu nit
    Poništi
  2. proslijedio/la je Tweet
    15. sij

    We are recruiting talented postdocs to join us to study and find better ways of treating , in the superb translational environment . Please rt and email me with CV and 3 references.

    Poništi
  3. proslijedio/la je Tweet
    13. sij

    - great session on SCLC - discussed heterogeneity, subtyping, drug sensitivities. Many opportunities to study this deadly disease with a team approach!

    Poništi
  4. proslijedio/la je Tweet
    10. sij

    Lots of good news, including in lung cancer in general, but still a flat survival for SCLC sadly

    Poništi
  5. proslijedio/la je Tweet
    8. sij

    The US saw its largest-ever single-year drop in overall cancer deaths, a 2.2% plunge spurred in part by a sharp decline in lung cancer deaths

    Poništi
  6. proslijedio/la je Tweet
    7. sij

    If you are in NYC and support the , please consider coming to a meeting on Tuesday Jan 14th in Battery Park to add your voice to mine (and others!) as I anticipate there might be a fair few antivaxxers present. Allow me to explain in a short thread 1/12

    Prikaži ovu nit
    Poništi
  7. 12. pro 2019.
    Poništi
  8. proslijedio/la je Tweet
    3. pro 2019.

    delivers a nice update on subtyping at . Are we getting closer to recognizing specific subtypes (NEUROD1, ASCL1, POU2F3, YAP1) and using that data to guide therapy? Very nice presentation and great work from Alvaro, ,

    Poništi
  9. proslijedio/la je Tweet
    18. stu 2019.

    November is - Unfortunately, this is still a disease that has a very low survival rate. Dr. Anirban Maitra, of MD Anderson, explains why early detection of the disease is so important.

    Poništi
  10. 12. stu 2019.

    List 2 things you like about being a scientist and tag 4 scientists: 1. Innovation; 2. Opportunity to make a difference.

    Poništi
  11. proslijedio/la je Tweet
    25. lis 2019.

    Friends and family — help me fundraise for rare cancer research at . Every donation to my ride will help make a difference!

    Poništi
  12. proslijedio/la je Tweet
    25. lis 2019.

    Former President Obama remembers Rep. Elijah Cummings: “Being a strong man includes being kind. There’s nothing weak about kindness and compassion. There’s nothing weak about looking out for others... You’re not a sucker to have integrity and to treat others with respect.”

    Poništi
  13. proslijedio/la je Tweet

    Stephen Liu, MD, discusses the known incidence of NRG1 fusion–positive cancers and the work being done to match targeted treatments with this patient subset

    Poništi
  14. 14. lis 2019.

    Shoutout to an amazing colleague and friend for this excellent article.

    Poništi
  15. proslijedio/la je Tweet

    2019 winner William Kaelin wrote a Perspective article for the journal in 2017 on Common pitfalls in preclinical cancer target validation that many have said should be 'required reading'. Access it for free here:

    Poništi
  16. proslijedio/la je Tweet

    It was a privilege to participate in the new medical podcast thedramaofdiagnosis to discuss pancreatic cancer. ⁩ ⁦

    Poništi
  17. proslijedio/la je Tweet
    1. lis 2019.

    Join us, & , on March 9-11 for an exciting conference on Transdisciplinary Cancer Interception: Leveraging Biology to Improve Prevention and Detection Please RT!

    Poništi
  18. proslijedio/la je Tweet
    27. ruj 2019.

    perhaps most exciting is combining these strategies in rational ways, highlighting key work by Lauren Byers and - the start of a lot of exciting work in this highly lethal subtype of lung cancer. Encourage listening to the session online!

    Prikaži ovu nit
    Poništi
  19. proslijedio/la je Tweet
    9. ruj 2019.

    CASPIAN study demonstrates improved outcomes w Durvalumab + EP vs EP alone. HR for OS 0.73. The K-M curves are strikingly similar between CASPIAN and IMpower133. A modest but consistent benefit of combination chemo/IO as first line treatment of ES .

    Poništi
  20. proslijedio/la je Tweet
    8. ruj 2019.

    Great work by at evaluating response to Cabozantinib beyond the first line in ROS-1 rearranged lung cancers

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·